Precision Diagnostics Opportunity to expand demand for Invivoscribe’s precision diagnostics platforms and companion diagnostics (CDx) in hematologic cancers by targeting pharma and biotech sponsors developing targeted therapies requiring robust MRD, B/TCR clonality testing, and actionable translocation assays.

Clinical Services Leverage LabPMM’s globally standardized flow cytometry and molecular testing services to offer end-to-end diagnostic support for drug development programs and outsourced clinical trial testing, enhancing partner timelines and data quality.

NGS Collaboration Capitalize on ongoing partnerships with NGS providers to co-develop and commercialize biomarker tests, opening cross-sell paths for sequencing-based panels and platform-agnostic assays across oncology indications.

Workflow Automation Market the new automated nucleic acid extraction and quantification system as a productivity win for labs, highlighting reduced hands-on time, higher throughput, and better integration with existing clinical workflows for oncology testing.

Global Expansion Target multinational pharma and CROs seeking standardized, compliant diagnostics across regions (US, Europe, Asia) to support global trials, regulatory submissions (IVDR), and consistent MRD and mutation monitoring.